IE
MLTX icon

Israel Englander’s MoonLake Immunotherapeutics MLTX Stock Holding History

Israel Englander’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4M Buy
636,187
+60,095
+10% +$1.09M ﹤0.01% 2071
2026
Q1 		$10.7M Sell
576,092
-226,630
-28% -$3.75M ﹤0.01% 2110
2025
Q4 		$10.6M Buy
802,722
+713,550
+800% +$8.42M ﹤0.01% 2207
2025
Q3 		$639K Buy
+89,172
New +$4.65M ﹤0.01% 4926
2025
Q2 		– Sell
-344,320
Closed -$13.5M – 6169
2025
Q1 		$13.5M Buy
+344,320
New +$14.8M 0.01% 1894
2024
Q4 		– Sell
-51,267
Closed -$2.62M – 6253
2024
Q3 		$2.58M Sell
51,267
-165,697
-76% -$7.76M ﹤0.01% 3466
2024
Q2 		$9.54M Buy
216,964
+195,989
+934% +$8.3M ﹤0.01% 2114
2024
Q1 		$1.05M Sell
20,975
-53,133
-72% -$2.88M ﹤0.01% 4251
2023
Q4 		$4.48M Buy
74,108
+43,578
+143% +$2.25M ﹤0.01% 2885
2023
Q3 		$1.74M Sell
30,530
-161,874
-84% -$8.94M ﹤0.01% 3690
2023
Q2 		$9.81M Buy
192,404
+157,333
+449% +$4.23M ﹤0.01% 2047
2023
Q1 		$750K Buy
+35,071
New +$590K ﹤0.01% 4329
2022
Q3 		– Sell
-28,090
Closed -$147K – 7335
2022
Q2 		$147K Sell
28,090
-120,135
-81% -$755K ﹤0.01% 5777
2022
Q1 		$1.65M Buy
148,225
+92,490
+166% +$920K ﹤0.01% 4060
2021
Q4 		$551K Hold
55,735
– – ﹤0.01% 4958
2021
Q3 		$555K Hold
55,735
– – ﹤0.01% 5254
2021
Q2 		$577K Buy
55,735
+35,735
+179% +$363K ﹤0.01% 5170
2021
Q1 		$204K Hold
20,000
– – ﹤0.01% 5486
2020
Q4 		$227K Buy
+20,000
New +$212K ﹤0.01% 4737

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Israel Englander's MLTX Position: Q2 2026 in Review

Israel Englander increased its MoonLake Immunotherapeutics (MLTX) stake by 10% in Q2 2026, buying an estimated $1.09M and bringing the position to 636,187 shares worth $12.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2071.

Israel Englander first reported a position in MLTX in Q4 2020 and has held it in 19 quarters since. The position peaked at $13.5M in Q1 2025. 171 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Israel Englander held 636,187 shares of MoonLake Immunotherapeutics worth $12.4M as of Q2 2026.
  • Israel Englander bought 60,095 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.09M.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2071 holding.
  • Israel Englander first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 19 quarters since.
  • Israel Englander's MoonLake Immunotherapeutics position peaked at $13.5M in Q1 2025.
  • 171 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.